{"id":58554,"date":"2026-03-02T14:07:21","date_gmt":"2026-03-02T06:07:21","guid":{"rendered":"https:\/\/flcube.com\/?p=58554"},"modified":"2026-03-02T14:07:22","modified_gmt":"2026-03-02T06:07:22","slug":"genfleets-gfh375-wins-cde-breakthrough-therapy-designation-oral-kras-g12d-inhibitor-for-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58554","title":{"rendered":"GenFleet&#8217;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC"},"content":{"rendered":"\n<p><strong>GenFleet Therapeutics (Shanghai) Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2595:HKG\">HKG:\u202f2595<\/a>)<\/strong> announced that <strong>GFH375<\/strong>, an <strong>oral KRAS G12D (ON\/OFF) inhibitor<\/strong>, has been granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by the <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>. The designation applies to <strong>KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC)<\/strong> patients who have received <strong>at least one prior systemic therapy<\/strong>, supported by <strong>best\u2011in\u2011class Phase\u202f1\/2 data<\/strong> demonstrating superior monotherapy efficacy and manageable safety.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GFH375<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Oral KRAS G12D (ON\/OFF) inhibitor<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>CDE Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>KRAS G12D\u2011mutant NSCLC (\u2265\u202f1 prior systemic therapy)<\/td><\/tr><tr><td><strong>Supporting Data<\/strong><\/td><td>Phase\u202f1\/2 GFH375X1101 study<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Best\u2011in\u2011class monotherapy efficacy in global KRAS G12D landscape<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-gfh375\">Drug Profile \u2013 GFH375<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>KRAS G12D (ON\/OFF) inhibition \u2013 targets GTP\/GDP exchange<\/td><\/tr><tr><td><strong>Effect<\/strong><\/td><td>Disrupts downstream pathway activation \u2192 inhibits tumor cell proliferation<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Oral, potent, highly selective<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td>KRAS G12D\u2011specific (vs. pan\u2011KRAS or G12C\u2011specific inhibitors)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-partnership-verastem-collaboration\">Global Partnership \u2013 Verastem Collaboration<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partnership Type<\/strong><\/td><td>Discovery and development collaboration<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Three novel oncology programs (RAS\/MAPK pathway\u2011driven cancers)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Verastem, Inc.<\/td><\/tr><tr><td><strong>Verastem Rights<\/strong><\/td><td>Exclusive option to license each compound<\/td><\/tr><tr><td><strong>Lead Program Selection<\/strong><\/td><td>Dec\u202f2023: Verastem selected GFH375\/VS\u20117375<\/td><\/tr><tr><td><strong>Verastem Territory<\/strong><\/td><td>Development and commercialization rights <strong>outside of China<\/strong><\/td><\/tr><tr><td><strong>GenFleet Retained Rights<\/strong><\/td><td><strong>Greater China<\/strong> (mainland, Hong Kong, Macau, Taiwan)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12D &#8220;Undruggable&#8221; Target:<\/strong> KRAS G12D is the <strong>most common KRAS mutation<\/strong> in NSCLC (~\u202f4% of all cases) and historically resistant to direct targeting; GFH375&#8217;s <strong>ON\/OFF mechanism<\/strong> and <strong>best\u2011in\u2011class efficacy<\/strong> validate a breakthrough approach.<\/li>\n\n\n\n<li><strong>Breakthrough Therapy Advantage:<\/strong> CDE <strong>BTD<\/strong> provides <strong>expedited review, enhanced CDE engagement, and potential priority review<\/strong> upon NDA submission\u2014accelerating time\u2011to\u2011market for this high\u2011unmet\u2011need population.<\/li>\n\n\n\n<li><strong>Verastem Global Expansion:<\/strong> The <strong>ex\u2011China partnership<\/strong> with Verastem ensures <strong>parallel global development<\/strong>, leveraging Verastem&#8217;s US\/EU regulatory expertise while GenFleet retains <strong>domestic commercial upside<\/strong>.<\/li>\n\n\n\n<li><strong>RAS\/MAPK Platform:<\/strong> The <strong>three\u2011program collaboration<\/strong> with Verastem establishes GenFleet as a <strong>leader in RAS pathway drug discovery<\/strong>, with potential for additional KRAS variant inhibitors and combination therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>KRAS G12D Prevalence<\/strong><\/td><td>~\u202f4% of NSCLC; ~\u202f12\u201115% of pancreatic cancer; ~\u202f5% of colorectal cancer\u2014large addressable market across solid tumors<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Mirati (BMS), Revolution Medicines, and others advancing KRAS G12D programs; GFH375&#8217;s best\u2011in\u2011class claim supported by head\u2011to\u2011head Phase\u202f1\/2 data<\/td><\/tr><tr><td><strong>Oral Administration Advantage<\/strong><\/td><td>vs. injectable competitors; improves patient compliance and outpatient management<\/td><\/tr><tr><td><strong>China\u2011First Development<\/strong><\/td><td>BTD in China potentially precedes US\/EU regulatory milestones, establishing GenFleet&#8217;s domestic leadership<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II\/III development timelines, global regulatory pathways, and commercial potential for GFH375. Actual results may differ due to risks including competitive KRAS G12D program advancements, combination therapy requirements, and Verastem execution outside China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200042_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030200042_c.\"><\/object><a id=\"wp-block-file--media-cf30c56e-afd4-4d1a-8747-d4f7a24749ce\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200042_c.pdf\">2026030200042_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200042_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cf30c56e-afd4-4d1a-8747-d4f7a24749ce\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\/OFF) inhibitor, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,16,1682,4345],"class_list":["post-58554","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-cancer","tag-genfleet-therapeutics","tag-hkg-2595"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenFleet&#039;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA). The designation applies to KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best\u2011in\u2011class Phase\u202f1\/2 data demonstrating superior monotherapy efficacy and manageable safety.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58554\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet&#039;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC\" \/>\n<meta property=\"og:description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA). The designation applies to KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best\u2011in\u2011class Phase\u202f1\/2 data demonstrating superior monotherapy efficacy and manageable safety.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58554\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T06:07:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T06:07:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58554#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58554\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet&#8217;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC\",\"datePublished\":\"2026-03-02T06:07:21+00:00\",\"dateModified\":\"2026-03-02T06:07:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58554\"},\"wordCount\":501,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"Cancer\",\"GenFleet Therapeutics\",\"HKG: 2595\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58554#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58554\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58554\",\"name\":\"GenFleet's GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-02T06:07:21+00:00\",\"dateModified\":\"2026-03-02T06:07:22+00:00\",\"description\":\"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\\\/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designation applies to KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best\u2011in\u2011class Phase\u202f1\\\/2 data demonstrating superior monotherapy efficacy and manageable safety.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58554#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58554\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58554#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet&#8217;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet's GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designation applies to KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best\u2011in\u2011class Phase\u202f1\/2 data demonstrating superior monotherapy efficacy and manageable safety.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58554","og_locale":"en_US","og_type":"article","og_title":"GenFleet's GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC","og_description":"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designation applies to KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best\u2011in\u2011class Phase\u202f1\/2 data demonstrating superior monotherapy efficacy and manageable safety.","og_url":"https:\/\/flcube.com\/?p=58554","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T06:07:21+00:00","article_modified_time":"2026-03-02T06:07:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58554#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58554"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet&#8217;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC","datePublished":"2026-03-02T06:07:21+00:00","dateModified":"2026-03-02T06:07:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58554"},"wordCount":501,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","Cancer","GenFleet Therapeutics","HKG: 2595"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58554#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58554","url":"https:\/\/flcube.com\/?p=58554","name":"GenFleet's GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-02T06:07:21+00:00","dateModified":"2026-03-02T06:07:22+00:00","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that GFH375, an oral KRAS G12D (ON\/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designation applies to KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best\u2011in\u2011class Phase\u202f1\/2 data demonstrating superior monotherapy efficacy and manageable safety.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58554#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58554"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58554#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet&#8217;s GFH375 Wins CDE Breakthrough Therapy Designation \u2013 Oral KRAS G12D Inhibitor for NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58554"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58554\/revisions"}],"predecessor-version":[{"id":58557,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58554\/revisions\/58557"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}